Traditionally viewed as a catalyst for cell migration, PI3K reveals a hidden regulatory mechanism. Here, authors uncover the PI3K's interaction with AP2 induces endocytosis, impeding cell migration ...

Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026. Click for more on RLAY stock.

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in ...

The enzyme PI3K plays a critical role in cell migration. Scientists have long understood this function. But researchers have recently unveiled that a subunit of this enzyme also has the ability to ...

A group of researchers have expanded conventional knowledge on a critical enzyme that controls cell migration. In a recent publication in the journal Nature Communications, they reported that ...